Streetbeat News

TARO

Taro Pharmaceutical Industries

http://www.taro.com

CEO

Uday Baldota

Employees

1,339

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

established in 1950, taro pharmaceutical industries ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. taro’s research programs and niche strategy have enabled the company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Taro Pharmaceutical Indus (NYSE:TARO) reported Q1 earnings of $0.27 per share, a 27.03% decrease YoY. However, the company's sales increased by 1.42% to $158.89 million.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 6:40 am

Nvidia shares are trading higher by over 5% after the company announced it would build the Israel-1 generative AI cloud supercomputer. Other stocks moving in Tuesday's mid-day session include QualTek Services, T2 Biosystems, Aclarion, Arlington Asset Investment Corp, and GreenLight Biosciences Holdings.

Portfolio Pulse from Lisa Levin

May 30, 2023 | 5:27 pm

Sun Pharmaceutical is considering making a proposal to acquire all outstanding ordinary shares of Taro Pharmaceuticals, causing Taro's shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 3:41 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.